NVO Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Novo Nordisk aims for a promising future with a fair value of 101.75
My Notes
Capture your thoughts, links and company narrative
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 88.08 |
| 52 Week High | DKK 148.15 |
| 52 Week Low | DKK 77.82 |
| Beta | 0.19 |
| 1 Month Change | 9.32% |
| 3 Month Change | -16.16% |
| 1 Year Change | -28.65% |
| 3 Year Change | 71.45% |
| 5 Year Change | 203.04% |
| Change since IPO | 48,496.13% |
Recent News & Updates
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Feb 20Novo Nordisk: Dips Like These Come Once Every Few Years
Feb 13Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Feb 05Recent updates
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Feb 20Novo Nordisk: Dips Like These Come Once Every Few Years
Feb 13Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Feb 05Novo Nordisk: Excellent Opportunity To Buy The Dip
Jan 15Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Jan 06Novo Nordisk Stock: A Rare Buying Opportunity
Dec 20Novo Nordisk: Just The Right Price (Rating Upgrade)
Dec 11Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
Nov 25Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
Nov 06Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Oct 21Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Sep 18Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now
Sep 10Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Novo Nordisk: Buy On Dips
Jul 04Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Jun 26Novo Nordisk: Leading The Fight Against Diabetes And Obesity
Jun 18Novo Nordisk: Considerable Growth Beyond Ozempic
May 27The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Shareholder Returns
| NVO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 13.1% | 0.6% | -0.4% |
| 1Y | -28.7% | -1.1% | 20.8% |
Return vs Industry: NVO underperformed the US Pharmaceuticals industry which returned -1.1% over the past year.
Return vs Market: NVO underperformed the US Market which returned 20.8% over the past year.
Price Volatility
| NVO volatility | |
|---|---|
| NVO Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 76,826 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NVO fundamental statistics | |
|---|---|
| Market cap | US$391.94b |
| Earnings (TTM) | US$14.15b |
| Revenue (TTM) | US$40.70b |
27.7x
P/E Ratio9.6x
P/S RatioIs NVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVO income statement (TTM) | |
|---|---|
| Revenue | DKK 290.40b |
| Cost of Revenue | DKK 43.56b |
| Gross Profit | DKK 246.84b |
| Other Expenses | DKK 145.86b |
| Earnings | DKK 100.99b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | 22.75 |
| Gross Margin | 85.00% |
| Net Profit Margin | 34.78% |
| Debt/Equity Ratio | 66.9% |
How did NVO perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield50%
Payout RatioDoes NVO pay a reliable dividends?
See NVO dividend history and benchmarks| Novo Nordisk dividend dates | |
|---|---|
| Ex Dividend Date | Mar 31 2025 |
| Dividend Pay Date | Apr 08 2025 |
| Days until Ex dividend | 37 days |
| Days until Dividend pay date | 45 days |
Does NVO pay a reliable dividends?
See NVO dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 22:33 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 68 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |